Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
- Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”)
- The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative
- Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry
- This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), with the management terming the findings as “positive” (https://nnw.fm/BGqZi ).
This marks a significant milestone for Lexaria, mainly since it builds upon its growing dataset around DehydraTECH amenability to GLP-1 formulation and oral delivery performance. In addition, it demonstrates DehydraTECH’s versatility and superiority, notably since the study achieved the desired outcomes without the proprietary salcaprozate sodium (“SNAC”) ingredient chemistry.
The results are significant, since published literature describing Rybelsus(R) noted that it occurs in simple monomeric form in the human gut. This presence has been attributed to SNAC, and the property has been known to allow the permeation of the gastric epithelium to deliver GLP-1 drugs into the bloodstream. Lexaria’s study clearly showed that semaglutide was efficiently released in the simulated gastric fluid environment. In all the cases, it was likely in monomeric form, a form previously achieved using the SNAC technology.
To realize this objective, Lexaria and the NRC team examined the molecular properties of DehydraTECH-processed semaglutide in comparison to the commercially available semaglutide formation, Rybelsus(R). They further used simulated gastric fluid, mimicking conditions in the human gut. In addition, they leveraged various testing methods such as dynamic light scattering (“DLS”), electrospray ionization mass spectrometry (“ESI-LCMS”), polyacrylamide gel electrophoresis (“PAGE”) and size exclusion chromatography (“SEC”).
The findings from this study offer a glimpse into Lexaria’s future. At the beginning of the year, its management noted its commitment to doubling down on GLP-1 studies for 2024, promising to make the year its biggest one yet. This milestone affirms this commitment while highlighting what is in line for Lexaria and its DehydraTECH technology. More importantly, it demonstrates the technology’s potential and versatility, in delivering various orally administered bioactive molecules more effectively (https://nnw.fm/TFNZU ).
Lexaria is making decent headway as it works toward carving out market share in the diabetes treatment market. In 2023, this market was valued at $79.25 billion. It is set to grow to $153.98 billion by 2032, representing a CAGR of 7% over the forecast period (2024-2032) (https://nnw.fm/EQm0C ). Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP-1 market. Its management is bullish about its current direction and is confident that its efforts will pay off in due time.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”)
- The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative
- Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry
- This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), with the management terming the findings as “positive” (https://nnw.fm/BGqZi ).
This marks a significant milestone for Lexaria, mainly since it builds upon its growing dataset around DehydraTECH amenability to GLP-1 formulation and oral delivery performance. In addition, it demonstrates DehydraTECH’s versatility and superiority, notably since the study achieved the desired outcomes without the proprietary salcaprozate sodium (“SNAC”) ingredient chemistry.
The results are significant, since published literature describing Rybelsus(R) noted that it occurs in simple monomeric form in the human gut. This presence has been attributed to SNAC, and the property has been known to allow the permeation of the gastric epithelium to deliver GLP-1 drugs into the bloodstream. Lexaria’s study clearly showed that semaglutide was efficiently released in the simulated gastric fluid environment. In all the cases, it was likely in monomeric form, a form previously achieved using the SNAC technology.
To realize this objective, Lexaria and the NRC team examined the molecular properties of DehydraTECH-processed semaglutide in comparison to the commercially available semaglutide formation, Rybelsus(R). They further used simulated gastric fluid, mimicking conditions in the human gut. In addition, they leveraged various testing methods such as dynamic light scattering (“DLS”), electrospray ionization mass spectrometry (“ESI-LCMS”), polyacrylamide gel electrophoresis (“PAGE”) and size exclusion chromatography (“SEC”).
The findings from this study offer a glimpse into Lexaria’s future. At the beginning of the year, its management noted its commitment to doubling down on GLP-1 studies for 2024, promising to make the year its biggest one yet. This milestone affirms this commitment while highlighting what is in line for Lexaria and its DehydraTECH technology. More importantly, it demonstrates the technology’s potential and versatility, in delivering various orally administered bioactive molecules more effectively (https://nnw.fm/TFNZU ).
Lexaria is making decent headway as it works toward carving out market share in the diabetes treatment market. In 2023, this market was valued at $79.25 billion. It is set to grow to $153.98 billion by 2032, representing a CAGR of 7% over the forecast period (2024-2032) (https://nnw.fm/EQm0C ). Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP-1 market. Its management is bullish about its current direction and is confident that its efforts will pay off in due time.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
